AI Terminal
BerGenBio
Report Publication Announcement • May 18, 2022
3555_rns_2022-05-18_5d149d75-d098-4667-b379-58405bc8ec52.pdf
Report Publication Announcement
Open in ViewerOpens in native device viewer
BERGENBIO ASA: INVITATION TO FIRST QUARTER 2022 RESULTS WEBCAST
Bergen, Norway, 18 May 2022 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, will be announcing its results for the first quarter 2022 on Tuesday 24 May 2022.
A presentation and live webcast by BerGenBio's senior management team will take place at 10:00 am CET, followed by a Q&A session.
The live webcast link will be available at www.bergenbio.com in the Investors/Financial Reports section and a recording will be available shortly after the webcast has finished.
The first quarter report and presentation will be made available on the Company's website in the Investors/Financial Reports section from 7:00am CET the same day.
-End-
Contacts
Martin Olin CEO, BerGenBio ASA [email protected]
Rune Skeie, CFO, BerGenBio ASA [email protected]
International Media Relations
Mary-Jane Elliott, Chris Welsh, Lucy Featherstone Consilium Strategic Communications [email protected] +44 20 3709 5700
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate bemcentinib a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and COVID-19.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com
Forward looking statements
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties, and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.